Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

Sarah L. Sammons, Keith W. Pratz, B. Douglas Smith, Judith E. Karp, Ashkan Emadi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)936-938
Number of pages3
JournalAmerican journal of hematology
Volume89
Issue number9
DOIs
StatePublished - Sep 2014

ASJC Scopus subject areas

  • Hematology

Cite this